{"article_title": "Latest blowback on Martin Shkreli, Turing and DaraprimMedCity News", "article_keywords": ["pharmaceutical", "turing", "blowback", "business", "shkreli", "medical", "startup", "treatment", "drug", "research", "york", "way", "martin", "daraprimmedcity", "sinai", "latest"], "article_url": "http://medcitynews.com/2015/09/martin-shkreli-turing-pharma-daraprim/", "article_text": "TOP STORIES\n\nMartin Shkreli and Turing Pharmaceuticals are getting the backlash they deserve \u2013 in the form of backhands across the face by the likes of John Carroll, as well as in-depth examinations by The New York Times.\n\nWhen you take a drug, and change the price from $13.50 to $750 and provide a response that\u2019s essentially:\n\nYou\u2019re going to have a problem.\n\nDr. Aberg of Mount Sinai said some hospitals will now find Daraprim too expensive to keep in stock, possibly resulting in treatment delays. She said that Mount Sinai is continuing to use the drug, but each use now requires a special review. \u201cThis seems to be all profit driven for somebody,\u201d she said, \u201cand I just think it\u2019s a very dangerous process.\u201d\n\nThe medical industry doesn\u2019t deal with patent trolls in the way the tech sector does. But drug-price spiking seems to be healthcare\u2019s generic alternative. \u2013 FierceBiotech, The New York Times & Forbes\n\nOn Friday the story was that Robert Califf, nominee to run the U.S. Food & Drug Administration, received $200,000 in consulting fees from pharmaceutical companies and the fees were donated to nonprofit groups. By Saturday, the story Califf has \u201cdeeper ties to the pharmaceutical industry than any F.D.A. commissioner in recent memory.\u201d What\u2019s next? \u2013 The Wall Street Journal & The New York Times\n\nLIFE SCIENCE\n\nCancer drug startup Deciphera has raised $75 million through New Leaf Venture Partners. Next stop: IPO? \u2013 Xconomy\n\nBioClinica acquired Synowledge to expand into the drug safety and regulatory business process outsourcing market. \u2013 PRNewswire\n\nShire \u2018s ADHD treatment INTUNIV won European Union marketing approval for use in children. \u2013 PRNewswire\n\nA better tool to look through drug research? The site, idodrugs.club, let\u2019s you search several databases at once and regurgitates any research on the topic in a clean(ish), Google-esque way. \u2013 TechCrunch\n\nThe latest study on Merck\u2019s c. diff drug is promising \u2013 it cuts the risk of infection by 10 percent. \u2013 Reuters\n\nPAYERS-PROVIDERS\n\nIndia home healthcare company Portea Medical closed $37.5 million in funding from the likes of Accel and Qualcomm Ventures. \u2013 Business Wire\n\nTECHNOLOGY\n\nAltusCampus, which has an online platform meant to improve managing continuing medical education in healthcare, is closing $800,000 in seed money (but will be raising a bigger A-round soon). \u2013 Xconomy\n\nMedData has acquired the Alegis Revenue Group. \u2013 Business Wire\n\nPOLITICS\n\nOne part of Obamacare everyone seems to hate: a rule that will increase premiums for small and mid-sized businesses. Look for changes in that part of the law if Congress can continue to play nice about it. \u2013 The New York Times\n\nA LITTLE BIT EXTRA\n\nHere\u2019s something to kick around the startup watercooler: a list of six tests that measure your potential as an entrepreneur (among them the Myers-Briggs Type Indicator, Gallup\u2019s Clifton Strength Finder, Marcus Buckingham StandOut Assessment and MAPP Career Assessment). Three questions: Have you taken them? How did you score? Do you agree with the list? \u2013 Startup Professionals Musings\n\nPhoto: Twitter", "article_metadata": {"description": "Also, the narrative shifts for FDA nominee Robert Califf, good news on Merck's c. diff treatment, and here's one part of Obamacare everyone hates.", "generator": "WordPress 4.5.2", "og": {"site_name": "MedCity News", "description": "Also, the narrative shifts for FDA nominee Robert Califf, good news on Merck's c. diff treatment, and here's one part of Obamacare everyone hates.", "title": "Morning Read: Is Martin Shkreli pharma\u2019s version of the patent troll?", "locale": "en_US", "image": "http://medcitynews.com/wp-content/uploads/2015/09/5xLOy8co.jpeg", "updated_time": "2015-10-02T11:53:54-04:00", "url": "http://medcitynews.com/2015/09/martin-shkreli-turing-pharma-daraprim/", "type": "article"}, "twitter": {"image": "http://medcitynews.com/wp-content/uploads/2015/09/5xLOy8co.jpeg", "description": "Also, the narrative shifts for FDA nominee Robert Califf, good news on Merck's c. diff treatment, and here's one part of Obamacare everyone hates.", "card": "summary", "title": "Latest blowback on Martin Shkreli, Turing and Daraprim"}, "robots": "noodp", "fb": {"app_id": 148725768475669}, "google-site-verification": "xudQg7nxVR9ifmMTY4Tf-0wVtX9b6rWLQd0utCweGOc", "keywords": "weight loss, obesity, overweight,diabetes,massachusetts,medical devices,obesity,startups,healthcare innovation, medcity news,medcity news,san francisco, startups, life sciences,accelerator,rock health,startup advice,startup funding,patient monitoring system, motion sensors ,dc,healthcare it,washington,foodborne pathogens, diagnostics company, diagnostic platforms,minimally invasive surgery, laser surgery,cambridge,dealflow,hospitals,wellpoint, healthways, health and wellness, employee wellness programs,investing,wellness,medtronic, shanghai innovation center, china, r&d,china,mdt,minneapolis,minnesota,publics,twin cities,ulcerative colitis, abbott labs, humira,abbott labs,doctors,pharmaceuticals,skin disorders, pharmaceuticals, md anderson cancer center,cancer,texas,renal denervation, st. jude medical,st. jude medical,stj,emr, ehr, electronic health records, electronic medical records, certified emr,certified emr,ehr,electronic health records,electronic medical records,advanced cellular technology,amyotrophic lateral sclerosis,embryonic stem cells,geron corporation,lou gehrig\\'s disease,macular degeneration,regenerative medicine,spinal cord damage,value-based healthcare system, obamacare, fee-for-service model,california,cleveland,health insurance,insurance,ohio,pennsylvania,politics,cancer treatment options library, aetna, aet, healthcare it,aet,aetna,health it,phi,philadelphia,Daraprim, generic drugs, Martin Shkreli, morning read, orphan drugs, Turing Pharmaceuticals, , MedCity News", "article": {"section": "Daily", "tag": "Turing Pharmaceuticals", "published_time": "2015-09-21T07:55:08-04:00", "modified_time": "2015-10-02T11:53:54-04:00"}, "viewport": "width=device-width,initial-scale=1.0,width=device-width,user-scalable=no,minimum-scale=1.0,maximum-scale=1.0"}, "_id": "\"57477af36914bd0286fd2280\"", "article_summary": "\u2013 The Wall Street Journal & The New York TimesLIFE SCIENCECancer drug startup Deciphera has raised $75 million through New Leaf Venture Partners.\n\u2013 PRNewswireA better tool to look through drug research?\n\u2013 TechCrunchThe latest study on Merck\u2019s c. diff drug is promising \u2013 it cuts the risk of infection by 10 percent.\nShe said that Mount Sinai is continuing to use the drug, but each use now requires a special review.\nDr. Aberg of Mount Sinai said some hospitals will now find Daraprim too expensive to keep in stock, possibly resulting in treatment delays."}